Psoriasis does affect the lungs, and the connection is stronger than most people realize. The same inflammatory process driving skin flares sends immune signals throughout the body, raising the risk of several lung conditions. In a large database study of over 472,000 people, those with psoriasis had significantly higher rates of asthma, emphysema, interstitial lung disease, and bronchiectasis compared to people without it.
Why a Skin Disease Reaches the Lungs
Psoriasis is not just a skin problem. The immune overreaction that causes plaques on your skin produces inflammatory signaling molecules that spill into the bloodstream and travel to distant organs, including the lungs. Three key players drive this process: TNF-alpha and IL-23 trigger the initial cascade, while IL-17 amplifies it downstream. These same molecules show up at elevated levels in lung tissue affected by conditions like COPD and asthma.
This shared biology explains why psoriasis and lung disease overlap so often. Your immune system doesn’t neatly contain inflammation to one organ. The more severe the psoriasis, the more inflammatory signals circulate, and the more likely other tissues are to sustain damage over time.
COPD and Psoriasis
Chronic obstructive pulmonary disease (COPD) has one of the strongest links to psoriasis of any lung condition. A large study using national health survey data found that people with psoriasis were about 54% more likely to have COPD after adjusting for age, sex, income, smoking, and other health conditions. Before those adjustments, the raw association was even higher, at roughly 2.6 times the odds of someone without psoriasis.
Smoking is a major risk factor for both conditions, and cigarette smoke triggers the same TNF-alpha and IL-17 pathways that are already overactive in psoriasis. That creates a compounding effect: if you have psoriasis and smoke, your lungs face inflammatory pressure from two directions at once. About 21% of psoriasis patients in one study showed airflow limitation (a hallmark of COPD), compared to lower rates in the general population.
Asthma Risk
Asthma is the most common pulmonary condition in people with psoriasis. In one cohort, 15% of people with psoriasis also had asthma. A meta-analysis pooling data from multiple studies found that psoriasis raised asthma risk by about 34 to 36%, regardless of whether the psoriasis was mild or moderate-to-severe. This makes sense biologically: both conditions involve an overactive immune response, and the inflammatory pathways overlap considerably.
Interstitial Lung Disease
Interstitial lung disease (ILD) involves scarring or inflammation in the tissue surrounding the air sacs in your lungs, making it progressively harder to breathe. A study published in BMC Pulmonary Medicine found ILD in 10% of psoriasis patients who were screened, split evenly between those with skin-only psoriasis and those with psoriatic arthritis. In a separate, larger analysis, psoriasis was associated with 2.5 times the odds of ILD.
ILD tends to develop quietly. Many patients have no symptoms in the early stages, and by the time breathing difficulties become noticeable, some degree of lung damage may already be present. This is one reason respiratory screening can be valuable for people with long-standing psoriasis, particularly if they also have joint involvement.
Less Common Lung Conditions
Beyond the major associations, psoriasis has been linked to several other pulmonary problems. Bronchiectasis, a condition where the airways become permanently widened and prone to infection, was 2.35 times more common in psoriasis patients. Emphysema carried a 2.54-fold increase. Pulmonary hypertension, which is high blood pressure in the arteries of the lungs, was 2.28 times more prevalent. Even lung cancer showed a modest association at 1.58 times the odds, though this may partly reflect shared risk factors like smoking.
Medications That Can Affect Your Lungs
Some psoriasis treatments carry their own respiratory considerations. Methotrexate, a widely used systemic medication, can in rare cases cause drug-induced pneumonitis, an inflammation of the lung tissue that mimics pneumonia. This complication is uncommon in psoriasis patients specifically, occurring less frequently than the 3 to 5% rate seen in rheumatoid arthritis patients on the same drug. Still, a new dry cough or unexplained shortness of breath while taking methotrexate warrants prompt attention.
Biologic therapies that target IL-17 have been associated with a 30 to 60% increase in respiratory tract infections compared to placebo in clinical trials. These are mostly upper respiratory infections: colds, sinus infections, sore throats, and bronchitis. Biologics targeting IL-23, a related but distinct pathway, may carry a similar risk, though the data is less definitive. The infections are generally mild, but they happen frequently enough that you should be aware of the pattern, especially during cold and flu season.
Symptoms Worth Paying Attention To
Lung involvement in psoriasis often develops gradually, without dramatic warning signs. The most commonly reported symptoms in studies of psoriatic arthritis patients with lung problems were chronic cough, shortness of breath (dyspnea), and changes in the color or smell of sputum. In one study, chronic cough appeared in about 4.5% of psoriatic arthritis patients, while shortness of breath affected 3.6%.
These numbers might seem small, but they represent people whose symptoms were significant enough to report. A persistent cough lasting more than a few weeks, breathlessness during activities that didn’t used to wind you, or recurrent chest infections are all signals that your lungs may be involved. This is especially relevant if you’ve had psoriasis for many years, have psoriatic arthritis, or are a current or former smoker. Pulmonary function testing and chest imaging can catch problems early, before they progress to a point where they limit your daily life.